Drug intelligence / Profile preview

APH-1503

Development stage: Preclinical
Lead developer: Aphios Pharma
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Oral

Overview

APH-1503 is an extended-release cannabinoid nanoparticle formulation being developed by Aphios Pharma for the treatment of generalized anxiety disorder (GAD). The drug utilizes Aphios' patented SuperFluids Polymer Nanospheres (SFS-PNS) technology to encapsulate cannabidiol (CBD) within biodegradable polymer spheres. This formulation is designed for once-daily oral administration, providing controlled release and significantly improved bioavailability—approximately five times higher than standard CBD formulations. By protecting the active ingredient from gastric acid degradation and hepatic first-pass metabolism, APH-1503 aims to provide sustained relief from anxiety symptoms without the sedation or dependency risks associated with benzodiazepines and SSRIs. It is currently in preclinical development.

Other names: APH-1503-Aphios-CB1 receptor-CB2 receptor-cannabinoid nanoparticles-generalized anxiety disorder (GAD)

Targets

GPR3 (G protein-coupled receptor 3)GPR6 (G protein-coupled receptor 6)GPR55 (G protein-coupled receptor 55)GPR12 (G protein-coupled receptor 12)CNR1 (Cannabinoid receptor 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on APH-1503.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APH-1503.

Explore the full profile